OKLAHOMA CITY: A three-year trial is looking into the impact of the diabetic drug liraglutide on dementia.
Volunteers will either be given a year-long course of the drug or a placebo and brain scans and cognitive tests to measure whether the medication can reverse the biological causes of Alzheimer’s.
If the trial is a success the medication could be given to patients with the condition within the next five to ten years…